{"id":708347,"date":"2024-07-31T16:56:01","date_gmt":"2024-07-31T16:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=708347"},"modified":"2024-07-31T16:56:01","modified_gmt":"2024-07-31T16:56:01","slug":"allergic-conjunctivitis-pipeline-assessment-2024-clinical-trials-fda-approvals-therapies-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/allergic-conjunctivitis-pipeline-assessment-2024-clinical-trials-fda-approvals-therapies-companies_708347.html","title":{"rendered":"Allergic Conjunctivitis Pipeline Assessment 2024 | Clinical Trials, FDA Approvals, Therapies, Companies"},"content":{"rendered":"
\n
\"Allergic<\/a><\/div>\n
\n
Allergic Conjunctivitis Pipeline Segment<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Allergic Conjunctivitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n

The Allergic Conjunctivitis Pipeline report 2024<\/a> embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

Allergic Conjunctivitis Pipeline Analysis<\/strong><\/p>\n

The report provides insights into:<\/strong><\/p>\n

The report provides detailed insights into the emerging therapies for the treatment of Allergic Conjunctivitis and the aggregate therapies developed by major pharma companies.<\/p>\n

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Allergic Conjunctivitis market.<\/p>\n

The report is built using data and information traced from the researcher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n

Analysis of Emerging Therapies by Phases<\/strong><\/a><\/p>\n

The report covers the emerging products under different phases of clinical development like –<\/strong><\/p>\n

Late-stage products (Phase III)<\/p>\n

Mid-stage products (Phase II)<\/p>\n

Early-stage product (Phase I)<\/p>\n

Pre-clinical and Discovery stage candidates<\/p>\n

Discontinued & Inactive candidates<\/p>\n

Route of Administration<\/p>\n

Allergic Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/strong><\/p>\n

Inhalation<\/p>\n

Inhalation\/Intravenous\/Oral<\/p>\n

Intranasal<\/p>\n

Intravenous<\/p>\n

Intravenous\/ Subcutaneous<\/p>\n

Oral<\/p>\n

Oral\/intranasal\/subcutaneous<\/p>\n

Parenteral<\/p>\n

Subcutaneous<\/p>\n

Molecule Type<\/p>\n

Products have been categorized under various Molecule types, such as<\/p>\n

Antibody<\/p>\n

Antisense oligonucleotides<\/p>\n

Immunotherapy<\/p>\n

Monoclonal antibody<\/p>\n

Peptides<\/p>\n

Protein<\/p>\n

Recombinant protein<\/p>\n

Small molecule<\/p>\n

Stem Cell<\/p>\n

Vaccine<\/p>\n

Learn How the Ongoing Clinical & Commercial Activities will Affect the Allergic Conjunctivitis Therapeutic Segment @<\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/allergic-conjunctivitis-pipeline-insight<\/a><\/strong><\/p>\n

Allergic Conjunctivitis Therapeutics Landscape<\/a><\/strong><\/p>\n

There are approx. 22+ key companies developing therapies for Allergic Conjunctivitis. Currently, Aldeyra Therapeutics is leading the therapeutics market with its Allergic Conjunctivitis drug candidates in the most advanced stage of clinical development.<\/p>\n

Leading Players in the Allergic Conjunctivitis Therapeutics Market<\/strong><\/a> Include:<\/p>\n

Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others.<\/p>\n

Allergic Conjunctivitis Emerging and Marketed Drugs Covered in the Report Include:<\/p>\n

Reproxalap: Aldeyra Therapeutics<\/p>\n

VSJ-110: Vanda Pharmaceuticals<\/p>\n

And Many More<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Report Introduction<\/p>\n

2. Executive Summary<\/p>\n

3. Allergic Conjunctivitis Current Treatment Patterns<\/p>\n

4. Allergic Conjunctivitis – DelveInsight’s Analytical Perspective<\/p>\n

5. Therapeutic Assessment<\/p>\n

6. Allergic Conjunctivitis Late Stage Products (Phase-III)<\/p>\n

7. Allergic Conjunctivitis Mid-Stage Products (Phase-II)<\/p>\n

8. Allergic Conjunctivitis Early Stage Products (Phase-I)<\/p>\n

9. Pre-clinical Products and Discovery Stage Products<\/p>\n

10. Inactive Products<\/p>\n

11. Dormant Products<\/p>\n

12. Allergic Conjunctivitis Discontinued Products<\/p>\n

13. Allergic Conjunctivitis Product Profiles<\/p>\n

14. Key Companies in the Allergic Conjunctivitis Market<\/p>\n

15. Key Products in the Allergic Conjunctivitis Therapeutics Segment<\/p>\n

16. Dormant and Discontinued Products<\/p>\n

17. Allergic Conjunctivitis Unmet Needs<\/p>\n

18. Allergic Conjunctivitis Future Perspectives<\/p>\n

19. Allergic Conjunctivitis Analyst Review<\/p>\n

20. Appendix<\/p>\n

21. Report Methodology<\/p>\n

Request for a free sample report @ <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Allergic Conjunctivitis Pipeline Segment As per DelveInsight\u2019s assessment, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Allergic Conjunctivitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-708347","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/708347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=708347"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/708347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=708347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=708347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=708347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}